News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Devgen NV has Successfully Entered the Hybrid Seed Market and is Ready for Expansion
August 27, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
GENT-ZWIJNAARDE, BELGIUM--(Marketwire - August 27, 2008) - Zwijnaarde, 26 August 2008 - Devgen NV (Euronext: DEVG) has successfully entered the hybrid seed market and is ready for expansion.
Twitter
LinkedIn
Facebook
Email
Print
Europe
MORE ON THIS TOPIC
Insights
Germany can produce biotech winners. Europe must back them better.
May 27, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Job Trends
Takeda cuts send layoffs soaring in May, rising year over year
May 19, 2026
·
4 min read
·
Angela Gabriel
Mergers & acquisitions
Mid-sized European drugmakers are snapping up US biotechs. Will the surge continue?
May 13, 2026
·
4 min read
·
Nick Paul Taylor
Huntington’s disease
UniQure eyes UK approval for embattled Huntington’s gene therapy after FDA quarrel
April 30, 2026
·
2 min read
·
Heather McKenzie
